Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666590 | 0.79 | — | — | |
| SCHEMBL4375225 | 0.75 | CA12 (0.47) | SMN1; SMN2 | |
| SCHEMBL6302015 | 0.75 | NPC1 (0.42) | SMN1; SMN2 | |
| SCHEMBL17842409 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL9813218 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL9244967 | 0.70 | TERT (0.43) | SMN1; SMN2 | |
| SCHEMBL72436 | 0.69 | — | — | |
| SCHEMBL9798176 | 0.68 | CYP3A4 (0.42) | SMN1; SMN2 | |
| SCHEMBL7141455 | 0.67 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL276358 | 0.65 | SMN1; SMN2 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | claimed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | claimed |
| EP-1005470-B1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1178967-B1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1584619-A1 | Derivatives of quinoline as inhibitors for MEK | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| CN-1219768-C | Quinoline derivatives as inhibitors of MEK enzymes | ASTRAZENECA AB (SE) | 2005-09-21 | — | — | CN | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6809106-B1 | ANTIPROLIFERATION AGENTS; SUCH AS 4-(2-METHOXYPHENOXY)-ANILINO-3-CHLORO-6,7-DIMETHOXYQUINOLINE | ASTRAZENECA AB (SE) | 2004-10-26 | — | — | US | disclosed |
| US-6638945-B1 | Pharmaceutical compositions and methods of treatment of proliferative disease such as cancer using said inhibitors of specific kinase enzymes, especially MEK enzymes, as well as novel quinoline derivatives as antigrowth agents | ASTRAZENECA AB (SE) | 2003-10-28 | — | — | US | disclosed |
| EP-1178966-B1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1178965-B1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | disclosed |